Mixed
Bariatric surgery (sleeve gastrectomy, gastric bypass, duodenal switch) provides superior long-term total weight loss (23.4%–40.7%) compared to GLP-1 receptor agonists (up to 25.3% with tirzepatide).
If your primary goal is maximum, durable weight loss, bariatric surgery currently outperforms GLP-1 medications in long-term results. However, surgery requires accepting permanent anatomical changes and potential risks. GLP-1s offer a less invasive alternative with significant weight loss, but require lifelong adherence to avoid regain and manage side effects. Choose based on your tolerance for invasiveness versus daily medication burden.
bariatric procedures such as sleeve gastrectomy and gastric bypass have demonstrated 10-year total weight loss (TWL) outcomes of 23.4% and 26.9%, respectively... Procedures that include a malabsorptive component, such as single-anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) and duodenal switch (DS), achieve even greater long-term TWL, at 34% for SADI-S and 40.7% for DS.
Why this rating
Based on long-term clinical trial data (10 years) and systematic reviews cited.
Source
Great Debates: Undergoing the Knife versus Pill-Popping—The Comparative Efficacy and Cost-Effectiveness of Bariatric Surgery and GLP-1 Receptor Agonists in the Management of Obesity
Paul J. Brosnihan et al. · The American Surgeon · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →